Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment

Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which...

Full description

Saved in:
Bibliographic Details
Published in:Nano letters 2023-01, Vol.23 (2), p.476-490
Main Authors: Jung, Mungyo, Kim, Hyeongseop, Hwang, Jung Won, Choi, Yejoo, Kang, Mikyung, Kim, Cheesue, Hong, Jihye, Lee, Na Kyung, Moon, Sangjun, Chang, Jong Wook, Choi, Suk-joo, Oh, Soo-young, Jang, Hyemin, Na, Duk L., Kim, Byung-Soo
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - metabolism
Alzheimer Disease - therapy
Animals
Cell Differentiation
Humans
Magnetic Iron Oxide Nanoparticles
Mesenchymal Stem Cells
Mice
Neurodegenerative Diseases
Wharton Jelly
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer’s disease (AD) is a neurodegenerative disease with multifactorial pathogenesis. However, most current therapeutic approaches for AD target a single pathophysiological mechanism, generally resulting in unsatisfactory therapeutic outcomes. Recently, mesenchymal stem cell (MSC) therapy, which targets multiple pathological mechanisms of AD, has been explored as a novel treatment. However, the low brain retention efficiency of administered MSCs limits their therapeutic efficacy. In addition, autologous MSCs from AD patients may have poor therapeutic abilities. Here, we overcome these limitations by developing iron oxide nanoparticle (IONP)-incorporated human Wharton’s jelly-derived MSCs (MSC-IONPs). IONPs promote therapeutic molecule expression in MSCs. Following intracerebro­ventricular injection, MSC-IONPs showed a higher brain retention efficiency under magnetic guidance. This potentiates the therapeutic efficacy of MSCs in murine models of AD. Furthermore, human Wharton’s jelly-derived allogeneic MSCs may exhibit higher therapeutic abilities than those of autologous MSCs in aged AD patients. This strategy may pave the way for developing MSC therapies for AD.
ISSN:1530-6984
1530-6992
DOI:10.1021/acs.nanolett.2c03682